Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Tuesday, June 20 • 10:30am - 11:45am
#215: The Evolving Model of Using Artificial Intelligence to Deliver Actionable Regulatory Intelligence

Sign up or log in to save this to your schedule and see who's attending!

Tweet Share
Component Type: Session
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

The breadth and scope of a regulatory intelligence function is often dependent on the knowledge of its employees, the tools they can access or the consultants they employ. What if we were able to employ machine learning and cognitive computing to help deliver actionable intelligence? This session will look at evolving models for Artificial Intelligence and the challenges in developing and validating these systems.

Join RA Community, Regulatory Intelligence Working Group for a follow up Round Table discussion at 1:00pm, Wednesday June 21st in the Community Corner.

Learning Objectives

Discuss artificial intelligence concepts, tools, and case studies in the development of actionable regulatory intelligence.

Chair

Linda F. Bowen

Speaker

Advances in Regulatory Intelligence Through Artificial Intelligence: Industry Perspective
Patrick K Brady, PharmD

Enigma Variations: The Use of Artificial Intelligence in Regulatory Decision Making
Tom Macfarlane, RAC


Moderators
avatar for Linda Bowen

Linda Bowen

Senior Director, Global Regulatory Science and Policy, Sanofi
Linda is Senior Director, Global Regulatory Science and Policy at Sanofi, and has held senior positions at Bayer and Block Drug/GSK, with global regulatory responsibilities for submissions, LCM and due diligence. She is an adjunct professor in the Temple University RA/QA Program... Read More →

Speakers
avatar for Linda Bowen

Linda Bowen

Senior Director, Global Regulatory Science and Policy, Sanofi
Linda is Senior Director, Global Regulatory Science and Policy at Sanofi, and has held senior positions at Bayer and Block Drug/GSK, with global regulatory responsibilities for submissions, LCM and due diligence. She is an adjunct professor in the Temple University RA/QA Program... Read More →
avatar for Patrick Brady

Patrick Brady

Regulatory Policy and Intelligence, Bayer
Dr. Patrick Brady is Vice President, Regulatory Affairs at Bayer. In this role, he leads Bayer’s global regulatory policy and intelligence activities. He has more than 10 years of experience in Regulatory Affairs. Prior to joining Bayer, Patrick led international science and re... Read More →
avatar for Tom Macfarlane

Tom Macfarlane

Director, Life Sciences, Accenture Accelerated R&D Services
A Neuroscientist by training, Tom has worked in most therapeutic areas during time at Ipsen, Parexel and as a freelance consultant. Now at Accenture, he continues to represent clients to EMA and to facilitate drug development strategies; but also works with emergent technologies... Read More →

Tuesday June 20, 2017 10:30am - 11:45am
S404d McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  05: Regulatory, Session